ESMO 2018 | Outlook for HR+/HER2- advanced breast cancer treatment

The addition of biological targeted therapies to hormone therapies in HR+/HER2- breast cancer is revolutionizing the landscape of treatment, and offering new hope to patients and physicians. Here, Ahmed Saadeddin, MD, FRCR, of the King Saud Bin AbdulAziz University for Health Sciences, Riyadh, Saudi Arabia, provides an outlook for HR+/HER2- advanced breast cancer treatment over the last 10 years, highlighting the success of key checkpoint inhibitors, aromatase inhibitors, and estrogen degraders, used in combination with hormone therapy, in first-line and second-line treatment. Dr Saadeddin also suggests a role for mTOR inhibitors combined with hormone therapy in the third-line treatment setting. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.